Compare JAZZ & PS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAZZ | PS |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.9B |
| IPO Year | 2007 | 2026 |
| Metric | JAZZ | PS |
|---|---|---|
| Price | $229.20 | $33.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 10 |
| Target Price | ★ $297.50 | $45.00 |
| AVG Volume (30 Days) | ★ 715.5K | 487.7K |
| Earning Date | 11-02-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 1.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $5.34 | $76.81 |
| P/E Ratio | $5,907.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $156.95 | $29.38 |
| 52 Week High | $266.38 | $60.40 |
| Indicator | JAZZ | PS |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 29.00 |
| Support Level | $222.49 | N/A |
| Resistance Level | $244.93 | $36.66 |
| Average True Range (ATR) | 8.63 | 4.12 |
| MACD | 0.33 | -1.42 |
| Stochastic Oscillator | 36.41 | 2.63 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Pershing Square Inc is a main alternative asset manager. It employs a disciplined, research-intensive approach to fundamental value investing to preserve and grow its permanent capital at high rates of return using a set of core investment principles and opportunistic asymmetric hedges. The group generates all of its revenue from management fees and performance fees. It conductbusiness and generates all of its revenues in the United States.